271 related articles for article (PubMed ID: 22798428)
1. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
[TBL] [Abstract][Full Text] [Related]
2. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
3. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
4. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
5. The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation.
Aslan JE; Baker SM; Loren CP; Haley KM; Itakura A; Pang J; Greenberg DL; David LL; Manser E; Chernoff J; McCarty OJ
Am J Physiol Cell Physiol; 2013 Sep; 305(5):C519-28. PubMed ID: 23784547
[TBL] [Abstract][Full Text] [Related]
6. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
7. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
8. Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.
Najahi-Missaoui W; Quach ND; Jenkins A; Dabke I; Somanath PR; Cummings BS
Pharmacol Res Perspect; 2019 Oct; 7(5):e00518. PubMed ID: 31516713
[TBL] [Abstract][Full Text] [Related]
9. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
10. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
11. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling.
Sementino E; Kadariya Y; Cheung M; Menges CW; Tan Y; Kukuyan AM; Shrestha U; Karchugina S; Cai KQ; Peri S; Duncan JS; Chernoff J; Testa JR
Mol Cancer Res; 2022 May; 20(5):699-711. PubMed ID: 35082167
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
Horiguchi A; Zheng R; Shen R; Nanus DM
Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
[TBL] [Abstract][Full Text] [Related]
14. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
15. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
16. p21-activated kinase links Rac/Cdc42 signaling to merlin.
Xiao GH; Beeser A; Chernoff J; Testa JR
J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
[TBL] [Abstract][Full Text] [Related]
17. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
[TBL] [Abstract][Full Text] [Related]
18. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.
López-Lago MA; Okada T; Murillo MM; Socci N; Giancotti FG
Mol Cell Biol; 2009 Aug; 29(15):4235-49. PubMed ID: 19451229
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
20. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
